How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2− Breast Cancer in the Post-RxPONDER Era?
Pilewskie M, Sevilimedu V, Eroglu I, Le T, Wang R, Morrow M, Braunstein LZ. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2− Breast Cancer in the Post-RxPONDER Era? Annals Of Surgical Oncology 2022, 29: 6267-6273. PMID: 35849294, PMCID: PMC10286823, DOI: 10.1245/s10434-022-12193-w.Peer-Reviewed Original ResearchConceptsSentinel lymph node biopsyAxillary lymph node dissectionAdjuvant therapy decisionsPostmenopausal womenNodal irradiationRecurrence scoreBreast cancerPositive nodesTherapy decisionsMedian age 62 yearsOncotype DX recurrence scorePT2-3 tumorsLymph node dissectionLymph node biopsyLow recurrence scoreAge 62 yearsDX recurrence scoreCT1-2N0MethodsPostmenopausal womenNodal pathologyPN0 stagePositive SLNRxPONDER trialAxillary stagingNode dissection